Original articleIncreased risk of infectious disease requiring hospitalization among patients with psoriasis: A population-based cohort
Section snippets
Data source
For this study we used data from the PHARMO Record Linkage System, which links various medical databases, including the National Medical Register of hospital discharge information and outpatient drug dispensing records (by general practitioners and medical specialists) concerning 2.5 million individuals who were ever residents in defined areas in The Netherlands.8, 9, 10, 11, 12 The hospital records included detailed information on primary and secondary diagnoses (coded according to the
Study population
A total of 154,452 people, 25,742 (16.7%) of whom had psoriasis, were followed up for an average of 6 years (Table I). Patients with psoriasis were older than the reference cohort (mean age 44.3 vs 38.2 years, P < .001), but the distribution between male and female gender was comparable. The proportion of subjects with a hospitalization of any kind in the 6 months before cohort entry was almost twice as high in the psoriasis cohort. During the available follow-up, 8.4% of the patients with
Discussion
The results of this large population-based cohort study indicate that the risk of serious infections requiring hospitalization is about two times higher in patients with psoriasis than in the general Dutch population. The ID risk was positively related to the psoriasis severity. It was highest in subjects with more severe psoriasis (ie, those who had used PUVA, a systemic therapy, or an inpatient treatment) showing one additional ID per 82 severe psoriasis cases, whereas there was one extra ID
References (35)
- et al.
Complexity of the association between psoriasis and comorbidities
J Invest Dermatol
(2009) - et al.
Disease concomitance in psoriasis
J Am Acad Dermatol
(1995) - et al.
Infectious complications of erythrodermic psoriasis
J Am Acad Dermatol
(1996) - et al.
Venous thromboembolism among new users of different oral contraceptives
Lancet
(1999) - et al.
Validation of pharmacy records in drug exposure assessment
J Clin Epidemiol
(1997) - et al.
Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?
Eur J Cancer
(2007) - et al.
COPD stage and risk of hospitalization for infectious disease
Chest
(2008) Infections and asthma
Clin Chest Med
(2006)- et al.
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
Lancet
(2007) - et al.
Comorbidities in dermatology
Dermatol Clin
(2009)
Prevalence of cardiovascular risk factors in patients with psoriasis
J Am Acad Dermatol
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
J Investig Dermatol Symp Proc
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004
J Am Acad Dermatol
Psoriasis is associated with increased beta-defensin genomic copy number
Nat Genet
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Nature
Genetically programmed differences in epidermal host defense between psoriasis and atopic dermatitis patients
PLoS One
Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes
Dermatologica
Cited by (102)
Infections in the era of immunobiologicals
2024, Anais Brasileiros de DermatologiaAssociation of psoriasis with risk of COVID-19: A 2-sample Mendelian randomization study
2022, Journal of the American Academy of DermatologyPsoriasis and pneumonia in the end-stage renal disease population
2022, American Journal of the Medical SciencesAssociation of herpes zoster and chronic inflammatory skin disease in US inpatients
2021, Journal of the American Academy of DermatologyPsoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey
2021, Journal of the American Academy of Dermatology
Supported by an unrestricted grant provided by Wyeth.
Disclosure: PHARMO is a research institute that performs financially supported studies for several pharmaceutical companies, including Wyeth and Novartis. Mr van den Haak has no financial or other relationship with any commercial companies related to this study or article. Drs Wakkee, de Vries, and Nijsten have no conflicts of interest to declare.